← 2026-11-16 archive

ARCHIVED · 1 LEFT · 0 CENTER · 1 RIGHT · Nov 16, 12:56 AM

Different Spin

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

One headline states the FDA "Doesn't Approve" the drug, while the other uses the stronger term "Rejects" and adds that the drug was "Closely Watched."

Archive
This is a stored Optics snapshot.It preserves the source map and wording analysis from 11/16/2026, 12:56:15 AM.

30-SECOND READ

What happenedThe FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.
What changedThe left frames it as "F.D.A. Rejects Closely Watched Lung Cancer Drug From China". The right frames it as "FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug".
ConfidenceLow. Two-source or narrow-bucket comparison.
Archive healthDeveloping · 2 sources · 2 buckets

WORDING GAP

45WORDING GAP

2 sources · 2 bias buckets · Low confidence

Different Spin. The left frames it as "F.D.A. Rejects Closely Watched Lung Cancer Drug From China". The right frames it as "FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug".

SOURCE MAP TIMELINE

Nov 15, 7:34 PM: Investor's Business Daily joined the source map.

Nov 15, 8:33 PM: New York Times - Business joined the source map.

Now: Wording Gap is 45/99 and story health is developing · 2 sources · 2 buckets.

ARCHIVED SOURCES

Center-right ·News report

FDA Doesn't Approve Summit's China-Developed Lung Cancer Drug

Doesn't Approve

The FDA said Summit Therapeutics' lung cancer drug ivonescimab, developed in China, failed to show a statistically significant survival benefit.

Open source
Center-left ·News report

F.D.A. Rejects Closely Watched Lung Cancer Drug From China

RejectsClosely Watched

The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.

Open source